Dechra Pharmaceuticals plc (LON:DPH)‘s stock had its “add” rating restated by stock analysts at Numis Securities Ltd in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. They currently have a GBX 1,890 ($24.48) target price on the stock. Numis Securities Ltd’s price objective would suggest a potential upside of 10.33% from the stock’s current price.
DPH has been the subject of a number of other research reports. Royal Bank of Canada boosted their target price on shares of Dechra Pharmaceuticals plc from GBX 1,630 ($21.11) to GBX 1,890 ($24.48) and gave the stock an “outperform” rating in a research note on Tuesday, March 14th. Stifel Nicolaus upped their price objective on shares of Dechra Pharmaceuticals plc from GBX 1,440 ($18.65) to GBX 1,550 ($20.08) and gave the company a “hold” rating in a research note on Tuesday, April 4th. Finally, Panmure Gordon reaffirmed an “under review” rating on shares of Dechra Pharmaceuticals plc in a research note on Thursday, April 20th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Dechra Pharmaceuticals plc presently has an average rating of “Buy” and a consensus price target of GBX 1,648.71 ($21.36).
Dechra Pharmaceuticals plc (DPH) opened at 1710.00 on Thursday. The stock’s 50 day moving average price is GBX 1,840.42 and its 200-day moving average price is GBX 1,620.69. Dechra Pharmaceuticals plc has a 12 month low of GBX 1,151.00 and a 12 month high of GBX 1,970.00. The stock’s market cap is GBX 1.59 billion.
COPYRIGHT VIOLATION NOTICE: “Dechra Pharmaceuticals plc (DPH) Stock Rating Reaffirmed by Numis Securities Ltd” was first reported by WKRB News and is the sole property of of WKRB News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.wkrb13.com/markets/2284433/dechra-pharmaceuticals-plc-dph-stock-rating-reaffirmed-by-numis-securities-ltd.html.
In related news, insider Ian Page sold 1,630 shares of the company’s stock in a transaction dated Tuesday, May 2nd. The shares were sold at an average price of GBX 1,715 ($22.22), for a total transaction of £27,954.50 ($36,210.49).
About Dechra Pharmaceuticals plc
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284433/dechra-pharmaceuticals-plc-dph-stock-rating-reaffirmed-by-numis-securities-ltd.html
Receive News & Ratings for Dechra Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals plc and related companies with MarketBeat.com's FREE daily email newsletter.